idelalisib + ruxolitinib

**Idelalisib + ruxolitinib** is a hypothetical or investigational combination of two small molecule inhibitors, **idelalisib** and **ruxolitinib**, each with distinct mechanisms of action. - **Idelalisib** is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), which is predominantly expressed in leukocytes and is essential for B-cell receptor signaling, cell proliferation, and survival pathways in lymphoid malignancies[8][9]. - **Ruxolitinib** is a Janus kinase (JAK) inhibitor, targeting JAK1 and JAK2, disrupting cytokine and growth factor signaling involved in myeloproliferative and inflammatory diseases[2][4][6]. - Both agents are approved as monotherapies or in combination with other drugs for hematologic malignancies (such as CLL, FL, SLL for idelalisib; myelofibrosis and polycythemia vera for ruxolitinib), but there is no evidence in the literature that they have been clinically combined or marketed as a fixed combination for any indication. - Any use of this combination would be considered experimental.

Other names

idelalisib + ruxolitinib